March 2011 Blog Posts (36)

Gathering on Capitol Hill Raises Awareness about the Importance and Value of Radiation Oncology

Leaders from the radiation oncology community – representing patients, physicians, providers, and manufacturers – met on Capitol Hill today to educate lawmakers and their staffs about the latest in radiation therapy technologies and techniques, improvements in patient care and the community's focus on patient safety in radiation therapy delivery. Representatives Sue Myrick (R-NC) and Lois Capps (D-CA) participated in today's briefing to share their personal experiences with…

Continue

Added by Peter Hofland, PhD on March 31, 2011 at 8:00am — No Comments

Data Demonstrate Crucial Role of PET-Guided Biopsy in Initial Breast Cancer Diagnosis

The Breast Journal recently published original prospective data confirming the technical validity of image-guided needle biopsy of suspicious breast cancer lesions using Positron Emission Mammography (PEM)-guidance. The study, which used the Naviscan high-resolution breast PET scanner, otherwise known as a PEM scanner, marks the… Continue

Added by Peter Hofland, PhD on March 31, 2011 at 5:00am — No Comments

FDA Approves Special Protocol Assessmen for Novel Therapeutic Targeting Cancer Metabolism

The U.S. Food & Drug Administration (FDA) has approved a Special Protocol Assessment (SPA) for a Phase III clinical trial of pegylated arginine deiminase (ADI-PEG 20, Polaris Group) in patients with advanced hepatocellular carcinoma (HCC).



ADI-PEG 20 is a novel protein therapeutic that has demonstrated anti-tumor activity and safety in Phase I & II clinical trials of patients with metastatic…

Continue

Added by Peter Hofland, PhD on March 31, 2011 at 5:00am — No Comments

Prolonging Quality of Life and Accessing Treatments for Late-stage Cancers are Issues of Growing Importance for Canadians

The Colorectal Cancer Association of Canada (CCAC), Canada's leading non-profit association dedicated to increasing awareness and education of colorectal cancer, supporting patients, and advocating for primary prevention, provincial screening programs as well as equal and timely access to effective treatments to improve patient outcomes earlier today announced findings from the Weighing Quality of Life in Cancer National Survey showing that an alarming 82% of Canadians have… Continue

Added by Peter Hofland, PhD on March 30, 2011 at 5:00am — No Comments

Motesanib Fails to Meet Primary Objective of Demonstrating an Improvement

Top-line results from the MONET1 pivotal Phase III trial evaluating motesanib (Amgen, Millennium: The Takeda Oncology Company and Takeda Pharmaceutical Company Limited), an investigational, orally-administered small molecule antagonist of VEGF… Continue

Added by Peter Hofland, PhD on March 30, 2011 at 5:00am — No Comments

National Cancer Institute Recognizes Marijuana’s Medical Benefit for People Living with Cancer

An accidental editorial change to the National Cancer Institute’s (NCI) website earlier this month has caused a major stir in medical marijuana and public policy circles, noting that the federal agency has uncharacteristically crossed a line in recognizing the medical efficacy of marijuana. NCI as part of the National Institutes of Health (NIH) has listed for the first time cannabis (medical marijuana) as a Complementary Alternative Medicine (CAM) in apparent contrast to information… Continue

Added by Peter Hofland, PhD on March 29, 2011 at 1:30am — No Comments

Many Elderly Men Are Undergoing Unnecessary PSA Screenings

A new study on the use of prostate-specific antigen (PSA)-based prostate cancer screening in the United States found that many elderly men may be undergoing unnecessary prostate cancer screenings. Using data from surveys conducted in 2000 and 2005, researchers report that nearly half of men in their seventies underwent PSA screening in the past year – almost double the screening rate of men in their early fifties, who are more likely to benefit from early prostate cancer diagnosis… Continue

Added by Peter Hofland, PhD on March 28, 2011 at 4:00pm — No Comments

New Larynx Cancer Treatment Saves Patients’ Voices

Jerry Young had had a routine endoscopy and assumed that the hoarseness that appeared in his voice was an after-effect of that exam. “If it doesn’t go away in a couple of weeks, make an appointment with an ENT,” his doctor told him. It didn’t and Young went to see an ear, nose and throat physician, who thought the redness on Young’s left vocal cord was caused by a virus.



Young was not convinced. His research made him suspect that cancer was the cause. A… Continue

Added by Peter Hofland, PhD on March 28, 2011 at 12:30pm — No Comments

First New Melanoma Therapy Option in More Than a Decade Changes Landscape for Patients

Earlier today the U.S. Food and Drug Administration announced the approval of ipilimumab (Yervoy, Bristol-Myers-Squib Company), an immunotherapy treatment to treat patients with advanced or late-stage (metastatic) melanoma. This new treatment option is the first therapy in more than thirteen years available to treat the most lethal form of skin cancer – melanoma. The drug will be used to treat melanoma patients whose cancer has spread to… Continue

Added by Peter Hofland, PhD on March 25, 2011 at 11:00am — No Comments

Analysis of Nearly 40 tumor Genomes in Multiple Myeloma Research Offers New Insights

A nationwide study by 20 institutes, including TGen, Broad Institute and Dana-Farber Cancer Institute, has unveiled the most comprehensive picture to date of the genetic blueprint of multiple myeloma also called plasma cell myeloma or Kahler's disease. Multiple myeloma is an all-too-common form of bone marrow cancer in which abnormal plasma cells (myeloma cells) multiply, raising the number of plasma cells to a higher than normal level. Since these cells normally make proteins, this… Continue

Added by Peter Hofland, PhD on March 23, 2011 at 11:30am — No Comments

First Detailed Database Shows How Neighborhood Affect Cancer Risk

Does living in a low-income, densely populated neighborhood such as San Francisco's Tenderloin district predispose you to a higher cancer risk than if you live in an upscale and suburban neighborhood such as San Diego's Rancho Santa Fe? Or vice versa? Scientists at the Cancer Prevention Institute of California (CPIC) now have the data that hold the answers.



Through their newly released study, Research Scientist… Continue

Added by Peter Hofland, PhD on March 17, 2011 at 12:30pm — No Comments

New Option for Breast Reconstruction for Women Lacking Abdominal Fatty Volume for Routine Procedure

Leading breast reconstruction surgeons Frank J. DellaCroce, M.D., FACS, Scott K. Sullivan, M.D., FACS, and Chris Trahan, M.D., have recently published data from groundbreaking work and pioneering description of a new technique that allows for women historically considered too thin for breast reconstruction with their own tissue to undergo their procedure with high success rates.



The article, 'Stacked Deep Inferior Epigastric Perforator Flap Breast… Continue

Added by Peter Hofland, PhD on March 17, 2011 at 7:30am — No Comments

Study Shows New Technologies Open the Door for Low Dose Breast-Specific Gamma Imaging

A new study by Craig Thiessen, M.D., Director of Radiology for West Houston Radiology L.L.P. and North Cypress Medical Center in Houston, presented this week at the National Consortium of Breast Centers Annual Meeting , found the improved photon sensitivity of new detector technologies such as PSPMTs and CZT should be capable of reducing the radiation dose patient… Continue

Added by Peter Hofland, PhD on March 17, 2011 at 6:00am — No Comments

First Diagnostic Chip Combines DNA Technologies to Help Classify AML Patients

Worldwide more than eight million people die of cancer each year. The chance of survival depending on the type of cancer, the stage at which it is diagnosed and the speed with which appropriate treatment is launched. Skyline Diagnostics, a Dutch company associated with the Erasmus Medical Center in Rotterdam, has developed a unique diagnostic test for…

Continue

Added by Peter Hofland, PhD on March 16, 2011 at 9:00pm — No Comments

New Drug Delivery System: Gold Nanoparticles use DNA to Deliver Doxorubicin, Improving Cancer Treatment

For the first time, scientists in Syracuse University's Chemistry Department have created a new drug delivery system expected to advance the effectiveness of cancer-killing drugs. The delivery system uses gold nanoparticles with attached DNA that binds to Doxorubicin or DOX, an anthracycline antibiotic which is closely related to the natural p… Continue

Added by Peter Hofland, PhD on March 16, 2011 at 5:00am — No Comments

New Surgical Technique Helps Adult Male Survivors of Childhood Cancer Regain Fertility

A new study has shown that a surgical technique called microdissection testicular sperm extraction (TESE) can effectively locate and extract viable sperm in more than one-third of adult male childhood cancer survivors who were previously considered sterile due to prior chemotherapy treatment. As a result, many of the men were subsequently able to father children with the help of in vitro fertilization. The findings offer a new option for many cancer survivors who want to have… Continue

Added by Peter Hofland, PhD on March 14, 2011 at 1:30pm — No Comments

Life After Cancer: Young Brain Tumor Survivor Is Now a Healthy and Active First-grader

In many ways, Isabelle Wagner is an ordinary first-grader: a creative, contented girl who loves drawing, making mud pies and climbing trees.



But one thing sets her apart: She has survived cancer. On Feb. 10, she passed the five-year anniversary of a lifesaving surgery at Lucile Packard Children’s Hospital to remove a malignant, golf-ball-sized tumor from her brain. It’s a significant milestone in a journey… Continue

Added by Peter Hofland, PhD on March 14, 2011 at 12:30am — No Comments

Top-line Results from Phase III Study with Aflibercept in Second-Line Non-Small Cell Lung Cancer do Not Meet Pre-specified Criteria for the Primary Endpoint of Improvement in Overall Survival

Results from the Phase III VITAL trial evaluating the investigational agent aflibercept (VEGF Trap; Sanofi-aventis Oncology and Regeneron) for the second-line treatment of non-small cell lung cancer (NSCLC) showed that adding aflibercept to the chemotherapy drug docetaxel did not meet the pre-specified criteria for the primary endpoint of improvement in overall survival… Continue

Added by Peter Hofland, PhD on March 10, 2011 at 1:30pm — No Comments

New Understanding of The Prostate Cancer Migration Process Offer Hope for Patients

Researchers from the University of Iowa and University of Alabama announced today that they are unraveling how prostate cancer cells grow and spread by identifying specific molecules which lead to changes in the migration and movement characteristics of prostate cancer cells. Findings from two separate studies were unveiled at the Prostate Cancer Research Program’s (PCRP’s)… Continue

Added by Peter Hofland, PhD on March 10, 2011 at 12:30pm — No Comments

Groundbreaking Results for a New, Cutting-edge Prostate Cancer Vaccine Presented at IMPaCT 2011

A cutting-edge scientific study reveals promising results for a prostate cancer vaccine. The nation’s most prestigious scientists and clinicians have joined together this week to reveal this and other groundbreaking discoveries at the Prostate Cancer Research Program’s (PCRP’s) Innovative Minds in Prostate Cancer Today (IMPaCT) conference in Orlando, Fla.



The Department of Defense Prostate Cancer Research… Continue

Added by Peter Hofland, PhD on March 10, 2011 at 12:30pm — No Comments

Monthly Archives

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2005

2004

2001

Register for free to view all the Onco'Zine - The International Oncology Network content:

ADVERTISEMENT/MEDIA PARTNER

Onco'Zine is present here

Bookmark / Share

CONNECT WITH US AND

JOIN THE CONVERSATION


© 2017   Created by Peter Hofland, PhD.   Powered by

Badges  |  Report an Issue  |  Terms of Service

Find us on Google+